Gilead's 'Pivotal Year' — Why An Analyst Is Bullish Enough To Upgrade SharesInvestors Business Daily • 01/19/21
The Gilead, Galapagos Pipeline Opportunities That Are Turning Morgan Stanley BullishBenzinga • 01/19/21
Gilead Stock 2021: Why The Biotech Stock Isn't Depending On Covid DrugsInvestors Business Daily • 01/15/21
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B VirusBusiness Wire • 01/12/21
Gilead Sciences, Inc. (GILD) Dan O'Day Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/11/21
Gilead CEO expects remdesivir to effectively treat Covid strains found in U.K., South AfricaCNBC • 01/11/21
Gilead updates 2020 guidance to raise sales outlook, tighten and lower top end of EPS rangeMarket Watch • 01/11/21
Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOsSeeking Alpha • 01/10/21
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid TumorsBusiness Wire • 01/06/21
Citigroup, Gilead, Groupon, Morgan Stanley, Spotify and More Tuesday Afternoon Analyst Calls24/7 Wall Street • 01/04/21
After Gilead Science's Year Of Acquisitions, 2021 Is When It Becomes An Oncology PowerhouseSeeking Alpha • 12/28/20